Easy. Accurate. Objective.
Through a series of comprehensive clinical studies, Nevisense has proven to deliver accurate, objective diagnostic information unavailable through any other method or device. The result is more informed clinical decisions, potentially leading to fewer missed melanomas and a reduction in unnecessary excisions.
Unique complementary information
Nevisense provides physicians with a unique EIS analysis of suspicious lesions, providing additional information in uncertain cases. For cutaneous lesions with unclear clinical or historical signs of melanoma, it allows physicians to obtain further information, complementary to visual examination, prior to a decision to excise.
Nevisense has a proven diagnostic accuracy in the detection of malignant melanoma in three consecutive studies with more than 4,000 lesions. In the pivotal study with a total inclusion of more than 2,400 lesions, the Nevisense system achieved a sensitivity of 97% in the target population. It also has a proven specificity of 38% on lesions with clinical suspicion of malignant melanoma, representing the potential reduction of unnecessary biopsies.
Visual inspection, whether through dermoscopy or with the naked eye, is inherently subjective. Nevisense enables physicians to complement their expertise with an objective analysis of cellular characteristics, thereby leading to more informed conclusions in difficult or borderline cases.
The Nevisense procedure fits easily within physicians’ normal patient flow. Compared with pathology which can take time to provide results, Nevisense provides immediate diagnostic information to the physician at point-of-care.